Clavis and Clovis Sign Licensing Deal for Cancer Drug
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
Uncategorized
[Company Profile] Ivivi Technologies
This targeted, a priori designed, micro-current is designed to enhance and accelerate the body’s natural healing processes to help repair injured tissue and to reduce related pain and inflammation.
Join Us at the 3rd Annual OneMedPlace Finance Forum
Over 100 companies and 500 investors are expected to attend the OneMedPlace Finance Forum, to take place from January 12-14 in San Francisco.
Micromet Signs $477M Deal with Sanofi-Aventis
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.
BioDelivery Sciences (NASDAQ: BDSI): Restarting the Catalyst Cycle
BDSI focuses on the niche market of pain management and supportive cancer care.
CardiAQ Valve Technologies Announces New Data, New Board Members
CVT’s system, currently under development, is the first self-conforming and self-anchoring technology for transcatheter mitral valve implantation (TVMI).
FDA Approves Centocor’s Psoriasis Treatment
After a long delay, Centocor Ortho Biotech’s psoriasis drug Stelara has been approved by the U.S. Food and Drug Administration.
Audiopoint Introduces Phone-Based EHR System
Earlier this month, Audiopoint added its voice to the list of companies developing EHR products.
Seaside Therapeutics Secures $30M to Fight Autism
Seaside Therapeutics has secured $30 million in funding from a private, unnamed family investment firm committed to finding treatments for autism and Fragile X syndrome.